These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15860163)

  • 41. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EU launches measures to stop diversion of cut-price drugs.
    Fleck F
    Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
    [No Abstract]   [Full Text] [Related]  

  • 44. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
    Dittmann RW
    Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Rising attention to the market to ratio meet demand of improving efficiency of pharmaceutical circulation--based on complicated variety and specification of drugs].
    Chen Z; Sun L
    Zhongguo Zhong Yao Za Zhi; 2010 May; 35(10):1357-60. PubMed ID: 20707215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implications of the accession of the Republic of Croatia to the European Union for Croatian health care system.
    Ostojić R; Bilas V; Franc S
    Coll Antropol; 2012 Sep; 36(3):717-27. PubMed ID: 23213925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 48. Outstanding regulatory aspects in the European pharmaceutical market.
    Kanavos P; Mossialos E
    Pharmacoeconomics; 1999 Jun; 15(6):519-33. PubMed ID: 10538326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccine supply, demand, and policy: a primer.
    Muzumdar JM; Cline RR
    J Am Pharm Assoc (2003); 2009; 49(4):e87-99. PubMed ID: 19589753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health policy regimes and the single European market.
    Altenstetter C
    J Health Polit Policy Law; 1992; 17(4):813-46. PubMed ID: 1299691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The development of regulation of medications turn-over in the EU and the USA in 1992-2020. Report I. The formation of normative legal base of pharmaceutical activities in the USA].
    Volskaya EA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Nov; 31(6):1426-1432. PubMed ID: 38142346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmaceutical research and development: a new system is needed.
    Prescrire Int; 2017 May; 26(182):130-135. PubMed ID: 30730675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.